Article (Scientific journals)
Prevalence and incidence of antibodies against SARS-CoV-2 among primary healthcare providers in Belgium during 1 year of the COVID-19 epidemic: prospective cohort study protocol.
Adriaenssens, Niels; Scholtes, Béatrice; Bruyndonckx, Robin et al.
2022In BMJ Open, 12 (1), p. 054688
Peer Reviewed verified by ORBi
 

Files


Full Text
e054688.full.pdf
Author postprint (518.02 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
COVID-19; general medicine (see internal medicine); primary care; public health; Belgium/epidemiology; Cohort Studies; Health Personnel; Humans; Incidence; Prevalence; Prospective Studies; Seroepidemiologic Studies; SARS-CoV-2
Abstract :
[en] ("[en] INTRODUCTION: National SARS-CoV-2 seroprevalence data provide essential information about population exposure to the virus and help predict the future course of the epidemic. Early cohort studies have suggested declines in levels of antibodies in individuals associated with, for example, illness severity, age and comorbidities. This protocol focuses on the seroprevalence among primary healthcare providers (PHCPs) in Belgium. PHCPs manage the vast majority of (COVID-19) patients and therefore play an essential role in the efficient organisation of healthcare. Currently, evidence is lacking on (1) how many PHCPs get infected with SARS-CoV-2 in Belgium, (2) the rate at which this happens, (3) their clinical spectrum, (4) their risk factors, (5) the effectiveness of the measures to prevent infection and (6) the accuracy of the serology-based point-of-care test (POCT) in a primary care setting. METHODS AND ANALYSIS: This study will be set up as a prospective cohort study. General practitioners (GPs) and other PHCPs (working in a GP practice) will be recruited via professional networks and professional media outlets to register online to participate. Registered GPs and other PHCPs will be asked at each testing point (n=9) to perform a capillary blood sample antibody POCT targeting IgM and IgG against the receptor-binding domain of SARS-CoV-2 and complete an online questionnaire. The primary outcomes are the prevalence and incidence of antibodies against SARS-CoV-2 in PHCPs during a 12-month follow-up period. Secondary outcomes include the longevity of antibodies against SARS-CoV-2. ETHICS AND DISSEMINATION: Ethical approval has been granted by the ethics committee of the University Hospital of Antwerp/University of Antwerp (Belgian registration number: 3002020000237). Alongside journal publications, dissemination activities include the publication of monthly reports to be shared with the participants and the general population through the publicly available website of the Belgian health authorities (Sciensano). TRIAL REGISTRATION NUMBER: NCT04779424.","[en] ","")
Disciplines :
Public health, health care sciences & services
Author, co-author :
Adriaenssens, Niels  ;  Department of Family Medicine and Population Health (FAMPOP), University of Antwerp, Antwerpen, Belgium niels.adriaenssens@uantwerpen.be
Scholtes, Béatrice   ;  Université de Liège - ULiège > Département des sciences cliniques > Médecine générale
Bruyndonckx, Robin ;  Interuniversity Institute for Biostatistics and Statistical Bioinformatics (I-BioStat), Data Science Institute, Hasselt University, Hasselt, Belgium ; Laboratory of Medical Microbiology, Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Antwerpen, Belgium
Verbakel, Jan Y ;  Department of Public Health and Primary Care, KU Leuven, Leuven, Belgium ; Nuffield Department of Primary Care Health Sciences, Oxford University, Oxford, UK
De Sutter, An;  Department of Public Health and Primary Care, Ghent University, Gent, Belgium
Heytens, Stefan ;  Department of Public Health and Primary Care, Ghent University, Gent, Belgium
Van den Bruel, Ann;  Department of Public Health and Primary Care, KU Leuven, Leuven, Belgium
Desombere, Isabelle;  Department of Infectious Diseases in Humans, Sciensano, Brussel, Belgium
Van Damme, Pierre;  Centre for the Evaluation of Vaccination, Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Antwerpen, Belgium
Goossens, Herman;  Laboratory of Medical Microbiology, Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Antwerpen, Belgium
Buret, Laetitia ;  Université de Liège - ULiège > Département des sciences cliniques > Médecine générale
Duysburgh, Els ;  Department of Epidemiology and Public Health, Sciensano, Brussel, Belgium
Coenen, Samuel  ;  Department of Family Medicine and Population Health (FAMPOP), University of Antwerp, Antwerpen, Belgium ; Laboratory of Medical Microbiology, Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Antwerpen, Belgium
More authors (3 more) Less
 These authors have contributed equally to this work.
Language :
English
Title :
Prevalence and incidence of antibodies against SARS-CoV-2 among primary healthcare providers in Belgium during 1 year of the COVID-19 epidemic: prospective cohort study protocol.
Publication date :
31 January 2022
Journal title :
BMJ Open
eISSN :
2044-6055
Publisher :
BMJ Publishing Group, Gb
Volume :
12
Issue :
1
Pages :
e054688
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 23 December 2022

Statistics


Number of views
22 (2 by ULiège)
Number of downloads
16 (0 by ULiège)

Scopus citations®
 
6
Scopus citations®
without self-citations
4
OpenCitations
 
4

Bibliography


Similar publications



Contact ORBi